Moderna, Inc. — Director's Dealing 2018

Dec 7, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2018-12-07

Reporting Person: LANGER ROBERT (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	11462402	Direct
Common Stock	14132	Indirect
Common Stock	14132	Indirect
Common Stock	14132	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series G Preferred Stock	$		Common Stock (4559)		Direct
Stock Option (Right to Buy)	$10.90	2026-02-23	Common Stock (23853)		Direct
Stock Option (Right to Buy)	$19.15	2026-08-10	Common Stock (80550)		Direct
Stock Option (Right to Buy)	$19.15	2026-08-10	Common Stock (24165)		Direct
Stock Option (Right to Buy)	$12.21	2027-02-23	Common Stock (42201)		Direct
Stock Option (Right to Buy)	$14.22	2028-02-28	Common Stock (40307)		Direct

Footnotes

F1: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F2: Each share of Series G Preferred Stock is convertible into shares of the Issuer's common stock, $0.0001 par value per share ("Common Stock") based on an applicable conversion ratio of 0.45872. Upon the closing of the Issuer's initial public offering, all shares of Series G Preferred Stock will convert into shares of Common Stock of the Issuer. The Series G Preferred Stock has no expiration date.

F3: This option is fully vested and exercisable.

F4: This option will become fully vested and exercisable on February 28, 2019.